Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies

https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.129

Abstract

Objective: to evaluate clinical-economic feasibility and impact of follitropin alfa on the state healthcare budget of the Russian Federation in the population of women with diagnosed infertility and poor ovarian response, who undergo treatment with assisted reproductive technologies (ART).

Material and methods. A cost minimization analysis to evaluate clinical-economic feasibility of follitropin alfa in women with infertility and poor ovarian response who underwent ART was performed. The model of the budget impact analysis included the costs required for the ovarian stimulation of patients distributed by various variants of their management. The current practice involved the application only of fixed dose combinations (FDC) of follitropin alfa + lutropin alfa. The expected practice suggested a change in the approach by shifting 25% of patients with poor ovarian response from FDC of follitropin alfa + lutropin alfa to follitropin alfa. A time horizon of modeling was 1 year.

Results. The cost minimization analysis demonstrated that the application of drug with international nonproprietary name follitropin alfa is characterized by the cost cut of 12,020 rubles (–21.56%) per patient compared with FDС of follitropin alpha + lutropin alpha. The results of budget impact analysis showed that a shift of 25% of population from FDC of follitropin alfa + lutropin alfa to follitropin alfa could cut direct medical costs by 7.96 million rubles per year (–5.39%).

Conclusion. Evaluation of clinical-economic feasibility and budget impact analysis showed that the application of follitropin alfa during ovarian stimulation in women with infertility and poor ovarian response leads to a decrease in budget expenses. 

About the Authors

K. A. Perova
Center for Expertise and Quality Control of Medical Care
Russian Federation

Leading Specialist, Department of Methodological Support for the Comprehensive Aassessment of Technologies in Healthcare, 

10/5 Khokhlovskiy Aly, Moscow 109028



D. G. Shchurov
Center for Expertise and Quality Control of Medical Care
Russian Federation

MD, PhD, Deputy Head of Development and External Communications Department, 

10/5 Khokhlovskiy Aly, Moscow 109028



D. V. Blinov
Institute for Preventive and Social Medicine
Russian Federation

MD, PhD, MBA, Head of Medical and Scientific Affairs, 

4/10 Sadovaya-Triumfalnaya Str., Moscow 127006



N. V. Bashmakova
Ural Scientific Research Institute of Maternity and Infancy Protection
Russian Federation

Dr. Med. Sc., Professor, Chief Resaercher, 

1 Repin Str., Ekaterinburg 620028



N. Z. Musina
Center for Expertise and Quality Control of Medical Care; Saint Petersburg State Chemical Pharmaceutical University
Russian Federation

PhD (Pharm.), Head of Development and External Communications Department, 10/5 Khokhlovskiy Aly, Moscow 109028;

Associate Professor, Chair of Pharmacy Management and Economics, 14 lit. А Professor Popov Str., Saint Petersburg 197022



References

1. Myers E.R., Eaton J.L., McElligott K.A., et al. Management of infertility. Comparative Effectiveness Review No. 217. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2015- 00004-I.) AHRQ Publication No. 19-EHC014-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2019. https://doi.org/10.23970/AHRQEPCCER217.

2. Clinical recommendations - Female infertility - 2021-2022-2023 (06/24/2021) - Approved by the Ministry of Health of the Russian Federation. Available at: https://moniiag.ru/wp-content/uploads/2019/07/Klinicheskie-rekomendatsii.-ZHenskoe-besplodie.pdf (in Russ.) (accessed 18.02.2022).

3. Ministry of Health of the Russian Federation. Letter of 05.05.2019 No. 15-4/I/2-1908 “Assisted reproductive technologies and artificial insemination”. Available at: https://minzdrav.samregion.ru/wp-content/uploads/sites/28/2020/01/pismo-minzdrava-rossii-ot-05_03_2019-n15-4-i-2-1908-o-n.pdf (in Russ.) (accessed 18.02.2022).

4. World Health Organization. Infertility. Available at: https://www.who.int/news-room/fact-sheets/detail/infertility (accessed 19.12.2021).

5. The total morbidity of the adult population of Russia in 2019. Statistical collection. Available at: http://www.demoscope.ru/weekly/2020/0879/biblio05.php (in Russ.) (accessed 18.02.2022).

6. Morbidity of the adult population of Russia in 2019 with a diagnosis established for the first time in life. Statistical materials. Available at: http://www.demoscope.ru/weekly/2020/0877/biblio05.php (in Russ.) (accessed 18.02.2022).

7. ART: Step-by-Step Guide. Available at: https://www.sart.org/patients/a-patients-guide-to-assisted-reproductive-technology/general-information/art-step-by-step-guide/ (accessed 15.12.2021).

8. Bosch E., Broer S., Griesinger G., et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reprod Open. 2020; 2020 (2): hoaa009. https://doi.org/10.1093/hropen/hoaa009.

9. Barakhoeva Z.B., Vovk L.A., Zorina I.V., et al. Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®). Obstetrics, Gynecology and Reproduction. 2018; 12 (3): 5–16 (in Russ.). https://doi.org/10.17749/2313-7347.2018.12.3.005-016.

10. Budani M.С., Fensore S., Marzio M., Tiboni G. Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a meta-analysis. Gynecol Endocrinol. 2021; 37 (5): 406–14. https://doi.org/10.1080/09513590.2020.1792437.

11. Lugan I., Febbraro S., Lecuelle H., et al. Bioequivalence of liquid and freeze-dried recombinant human follicle-stimulating hormone. Curr Med Res Opin. 2005; 21 (1): 121–5. https://doi.org/10.1185/030079904X18027.

12. Voortman G., Post van de J., Schoemaker C., Gerven J. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injection and syringe. Hum Reprod. 1999; 14 (7): 1698–702. https://doi.org/10.1093/humrep/14.7.1698.

13. List of interchangeable medicines. Available at: https://grls.rosminzdrav.ru/Forum/Files/243339/%D0%9F%D0%B5%D1%80%D0%B5%D1%87%D0%B5%D0%BD%D1%8C%20%D0%92%D0%97%20(24.01.2022).xlsb (in Russ.) (accessed 17.02.2022).

14. Humaidan P., Chin W., Rogoff D., et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017; 32 (3): 544–55. https://doi.org/10.1093/humrep/dew360.

15. Unified information system in the field of procurement. Available at: https://zakupki.gov.ru/epz/main/public/home.html (in Russ.) (accessed 28.11.2021).

16. Register of assisted reproductive technologies. Russian Association of Human Reproduction. Report for 2019. Available at: https://www.rahr.ru/d_registr_otchet/RegistrART2019.pdf (in Russ.) (accessed 19.12.2021).

17. Barakhoeva Z., Vovk L., Fetisova Y., et al. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha. Eur J Obstet Gynecol Reprod Biol. 2019; 241: 6–12. https://doi.org/10.1016/j.ejogrb.2019.07.032.

18. Kamilova D.P., Ovchinnikova M.M., Ablyaeva E.S., et al. An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data. Obstetrics, Gynecology and Reproduction. 2021; 15 (1): 5–21 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.212.

19. Polzikov M., Kamilova D., Ovchinnikova M., et al. P–669 “FOLLITROPIN”: a retrospective, observational study comparing the efficacy of follitropin alpha biosimilar therapy in different ovarian stimulation protocols: real-world data. Hum Reprod. 2021; 36 (Suppl. 1): deab130.668. https://doi.org/10.1093/humrep/deab130.668.


Review

For citations:


Perova K.A., Shchurov D.G., Blinov D.V., Bashmakova N.V., Musina N.Z. Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):40-50. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.129

Views: 214


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)